Yao W. Zhang

220 Handan Road
Shanghai, 200433, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 64 publications

Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial.

Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial.

Journal: BMJ open

Published: March 25, 2026

The JAK1 inhibitor golidocitinib boosts therapeutic potency of DLL3-targeted CAR-T therapy for small cell lung cancer.

The JAK1 inhibitor golidocitinib boosts therapeutic potency of DLL3-targeted CAR-T therapy for small cell lung cancer.

Journal: Pharmacological research

Published: March 14, 2026

EZH2 inhibition overcomes immune evasion in lung adenocarcinoma by restoring CCL5-mediated T-cell recruitment and MHC class I antigen presentation.

EZH2 inhibition overcomes immune evasion in lung adenocarcinoma by restoring CCL5-mediated T-cell recruitment and MHC class I antigen presentation.

Journal: Acta biochimica et biophysica Sinica

Published: March 03, 2026

Narrative review of the similarities and differences between immune checkpoint inhibitor- and antibody-drug conjugate-associated pneumonitis.

Narrative review of the similarities and differences between immune checkpoint inhibitor- and antibody-drug conjugate-associated pneumonitis.

Journal: Translational lung cancer research

Published: February 06, 2026

B3GNT3 facilitates NFKB2 processing and non-canonical NF-κB activation to drive lung adenocarcinoma progression.

B3GNT3 facilitates NFKB2 processing and non-canonical NF-κB activation to drive lung adenocarcinoma progression.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: January 06, 2026

WNT7A correlates with immunosuppression and predicts adverse prognosis in lung adenocarcinoma: Potential implication of the NF-κB/CCL2 Axis.

WNT7A correlates with immunosuppression and predicts adverse prognosis in lung adenocarcinoma: Potential implication of the NF-κB/CCL2 Axis.

Journal: Cytokine

Published: December 13, 2025

Distinctive molecular architectures of Gq- and Gi-coupled GLP-1 receptors.

Distinctive molecular architectures of Gq- and Gi-coupled GLP-1 receptors.

Journal: Acta pharmaceutica Sinica. B

Published: December 11, 2025

Hydrogel-forming microneedles for the treatment of skin diseases.

Hydrogel-forming microneedles for the treatment of skin diseases.

Journal: Materials today. Bio

Published: June 10, 2025

Synthetic Lethal Co-Mutations in DNA Damage Response Pathways Predict Response to Immunotherapy in Pan-Cancer.

Synthetic Lethal Co-Mutations in DNA Damage Response Pathways Predict Response to Immunotherapy in Pan-Cancer.

Journal: JCO precision oncology

Published: May 29, 2025

Evaluation of gefitinib alone or combined with bevacizumab in patients with EGFR L858R-positive advanced non-squamous non-small cell lung cancer: an open-label, randomized, phase 2 trial (BEVA-FLFX-001) with exploratory analysis of plasma biomarkers.

Evaluation of gefitinib alone or combined with bevacizumab in patients with EGFR L858R-positive advanced non-squamous non-small cell lung cancer: an open-label, randomized, phase 2 trial (BEVA-FLFX-001) with exploratory analysis of plasma biomarkers.

Journal: Translational lung cancer research

Published: May 08, 2025

Divergent activation patterns of BRS3 revealed by two Chinese herb-derived agonists.

Divergent activation patterns of BRS3 revealed by two Chinese herb-derived agonists.

Journal: Acta pharmaceutica Sinica. B

Published: February 25, 2025

Structural pharmacology and mechanisms of GLP-1R signaling.

Structural pharmacology and mechanisms of GLP-1R signaling.

Journal: Trends in pharmacological sciences

Published: February 11, 2025

Showing 1-12 of 64

Last Updated: 09/26/2026